Abstract
Transforming growth factor-beta (TGF-β) is a multifunctional growth factor with a wide range of potential effects on growth, differentiation, extracellular matrix accumulation and the immune system. It has been implicated in many cardiovascular disorders. TGF-β actions are mediated via a complex between its type I and type II receptors resulting in the phosphorylation of receptor-specific Smads followed by their passage to the nucleus where they influence many transcriptional responses. TGF-β has important roles in the development of the neointima and constrictive remodeling associated with angioplasty. In atherosclerosis its actions are yet to be fully elucidated but its ability to control the immune system has profound effects on lesion development, particularly by influencing the types of lesions that develop. TGF-β can also induce arteriogenesis and markedly influences angiogenic processes, possessing both pro- and anti-angiogenic effects. It is also a major contributor to the development of various cardiovascular fibrotic disorders including those in the vasculature, heart and kidney. Targeting TGF-β prevents neointima formation and the constrictive remodeling associated with angioplasty and also prevents the development of many fibrotic disorders. This review summarizes TGF-β signaling pathways, the mechanisms by which TGF-β contributes to many of these cardiovascular diseases and examines the therapeutic potential of targeting TGF-β actions in preventing these disorders.
Keywords: transcription, dna binding proteins, transforming growth factor, antifibrotic effects
Current Vascular Pharmacology
Title: Transforming Growth Factor-β, Cell Signaling and Cardiovascular Disorders
Volume: 3 Issue: 1
Author(s): Alex Agrotis, Natalia Kalinina and Alex Bobik
Affiliation:
Keywords: transcription, dna binding proteins, transforming growth factor, antifibrotic effects
Abstract: Transforming growth factor-beta (TGF-β) is a multifunctional growth factor with a wide range of potential effects on growth, differentiation, extracellular matrix accumulation and the immune system. It has been implicated in many cardiovascular disorders. TGF-β actions are mediated via a complex between its type I and type II receptors resulting in the phosphorylation of receptor-specific Smads followed by their passage to the nucleus where they influence many transcriptional responses. TGF-β has important roles in the development of the neointima and constrictive remodeling associated with angioplasty. In atherosclerosis its actions are yet to be fully elucidated but its ability to control the immune system has profound effects on lesion development, particularly by influencing the types of lesions that develop. TGF-β can also induce arteriogenesis and markedly influences angiogenic processes, possessing both pro- and anti-angiogenic effects. It is also a major contributor to the development of various cardiovascular fibrotic disorders including those in the vasculature, heart and kidney. Targeting TGF-β prevents neointima formation and the constrictive remodeling associated with angioplasty and also prevents the development of many fibrotic disorders. This review summarizes TGF-β signaling pathways, the mechanisms by which TGF-β contributes to many of these cardiovascular diseases and examines the therapeutic potential of targeting TGF-β actions in preventing these disorders.
Export Options
About this article
Cite this article as:
Agrotis Alex, Kalinina Natalia and Bobik Alex, Transforming Growth Factor-β, Cell Signaling and Cardiovascular Disorders, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773951
DOI https://dx.doi.org/10.2174/1570161052773951 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Editorial [Hot Topic: The Type XIV Family of C-type Lectin-like Domain (CTLD) Containing Proteins (Guest Editor: Edward M. Conway)]
Current Drug Targets The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Cellular Repressor of E1A-stimulated Genes, A New Potential Therapeutic Target for Atherosclerosis
Current Drug Targets Herb-Drug Interactions: An Evidence Based Approach
Current Medicinal Chemistry Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews Neuronal Nitric Oxide Synthase and Sympathetic Nerve Activity in Neurovascular and Metabolic Systems
Current Neurovascular Research Cannabinoid Modulation of Perivascular Sympathetic and Sensory Neurotransmission
Current Vascular Pharmacology Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research Angiotensin II-Vasopressin Interactions in The Regulation of Cardiovascular Functions. Evidence for an Impaired Hormonal Sympathetic Reflex in Hypertension and Congestive Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Nitrogen Containing Privileged Structures and their Solid Phase Combinatorial Synthesis
Combinatorial Chemistry & High Throughput Screening Klotho-FGF23, Cardiovascular Disease, and Vascular Calcification: Black or White?
Current Vascular Pharmacology Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Current Diabetes Reviews Systemic Sclerosis at the Cellular Level: Molecular Pathways of Pathogenesis and its Implication on Future Drug Design
Current Medicinal Chemistry Pleuroparenchymal Fibroelastosis: Associations and Underlying Conditions
Current Respiratory Medicine Reviews Reactive Oxygen Species, Nitric Oxide and Hypertensive Endothelial Dysfunction
Current Hypertension Reviews Airway Clearance of Apoptotic Cells in COPD
Current Drug Targets Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry